BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ye D, Li FY, Lam KS, Li H, Jia W, Wang Y, Man K, Lo CM, Li X, Xu A. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut. 2012;61:1058-1067. [PMID: 22253482 DOI: 10.1136/gutjnl-2011-300269] [Cited by in Crossref: 125] [Cited by in F6Publishing: 124] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Aron-wisnewsky J, Pepin J. New insights in the pathophysiology of chronic intermittent hypoxia-induced NASH: the role of gut–liver axis impairment. Thorax 2015;70:713-5. [DOI: 10.1136/thoraxjnl-2015-207212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
2 Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2019;16:145-59. [DOI: 10.1038/s41575-018-0082-x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 185] [Article Influence: 44.3] [Reference Citation Analysis]
3 Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther 2019;50:144-58. [PMID: 31149745 DOI: 10.1111/apt.15314] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
4 Ramadori P, Kroy D, Streetz KL. Immunoregulation by lipids during the development of non-alcoholic steatohepatitis. Hepatobiliary Surg Nutr 2015;4:11-23. [PMID: 25713801 DOI: 10.3978/j.issn.2304-3881.2015.01.02] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
5 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Reference Citation Analysis]
6 Caligiuri A, Gentilini A, Marra F. Molecular Pathogenesis of NASH. Int J Mol Sci. 2016;17. [PMID: 27657051 DOI: 10.3390/ijms17091575] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 13.2] [Reference Citation Analysis]
7 Fotschki B, Laparra JM, Sójka M. Raspberry Polyphenolic Extract Regulates Obesogenic Signals in Hepatocytes. Molecules 2018;23:E2103. [PMID: 30134638 DOI: 10.3390/molecules23092103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
8 Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal Barrier in Human Health and Disease. Int J Environ Res Public Health 2021;18:12836. [PMID: 34886561 DOI: 10.3390/ijerph182312836] [Reference Citation Analysis]
9 Portela-Cidade JP, Borges-Canha M, Leite-Moreira AF, Pimentel-Nunes P. Systematic Review of the Relation Between Intestinal Microbiota and Toll-Like Receptors in the Metabolic Syndrome: What Do We Know So Far? GE Port J Gastroenterol 2015;22:240-58. [PMID: 28868416 DOI: 10.1016/j.jpge.2015.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Hundertmark J, Krenkel O, Tacke F. Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease. Front Immunol 2018;9:2418. [PMID: 30405618 DOI: 10.3389/fimmu.2018.02418] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
11 Du X, Wu Z, Xu Y, Liu Y, Liu W, Wang T, Li C, Zhang C, Yi F, Gao L, Liang X, Ma C. Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice. Cell Mol Immunol 2019;16:878-86. [PMID: 29735977 DOI: 10.1038/s41423-018-0032-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
12 Dunys J, Duplan E, Checler F. The transcription factor X-box binding protein-1 in neurodegenerative diseases. Mol Neurodegener. 2014;9:35. [PMID: 25216759 DOI: 10.1186/1750-1326-9-35] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
13 Lo BC, Chen GY, Núñez G, Caruso R. Gut microbiota and systemic immunity in health and disease. Int Immunol 2021;33:197-209. [PMID: 33367688 DOI: 10.1093/intimm/dxaa079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
15 Chiu CC, Ching YH, Li YP, Liu JY, Huang YT, Huang YW, Yang SS, Huang WC, Chuang HL. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. Nutrients 2017;9:E1220. [PMID: 29113135 DOI: 10.3390/nu9111220] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 12.4] [Reference Citation Analysis]
16 Zhang Y, Wu B, Zhang H, Ge X, Ying S, Hu M, Li W, Huang Y, Wang L, Chen C, Shan X, Liang G. Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease. J Cell Mol Med 2018;22:936-47. [PMID: 29077272 DOI: 10.1111/jcmm.13395] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
17 Mukherjee R, Moreno-Fernandez ME, Giles DA, Cappelletti M, Stankiewicz TE, Chan CC, Divanovic S. Nicotinamide adenine dinucleotide phosphate (reduced) oxidase 2 modulates inflammatory vigor during nonalcoholic fatty liver disease progression in mice. Hepatol Commun 2018;2:546-60. [PMID: 29761170 DOI: 10.1002/hep4.1162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
18 Kiziltas S, Ata P, Colak Y, Mesçi B, Senates E, Enc F, Ulasoglu C, Tuncer I, Oguz A. TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls. Metab Syndr Relat Disord. 2014;12:165-170. [PMID: 24443993 DOI: 10.1089/met.2013.0120] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
19 Yang J, Ma XJ, Li L, Wang L, Chen YG, Liu J, Luo Y, Zhuang ZJ, Yang WJ, Zang SF, Shi JP. Berberine ameliorates non-alcoholic steatohepatitis in ApoE-/- mice. Exp Ther Med 2017;14:4134-40. [PMID: 29075339 DOI: 10.3892/etm.2017.5051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
20 Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, Qi Y, Fang ZZ, Takahashi S, Tanaka N, Desai D, Amin SG, Albert I, Patterson AD, Gonzalez FJ. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125:386-402. [PMID: 25500885 DOI: 10.1172/jci76738] [Cited by in Crossref: 330] [Cited by in F6Publishing: 216] [Article Influence: 41.3] [Reference Citation Analysis]
21 Chang B, Xu MJ, Zhou Z, Cai Y, Li M, Wang W, Feng D, Bertola A, Wang H, Kunos G, Gao B. Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: An important role for CXCL1. Hepatology. 2015;62:1070-1085. [PMID: 26033752 DOI: 10.1002/hep.27921] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 13.4] [Reference Citation Analysis]
22 Arias-Loste MT, Iruzubieta P, Puente Á, Ramos D, Santa Cruz C, Estébanez Á, Llerena S, Alonso-Martín C, San Segundo D, Álvarez L, López Useros A, Fábrega E, López-Hoyos M, Crespo J. Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2016;17:E1878. [PMID: 27834919 DOI: 10.3390/ijms17111878] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
23 Narayanan S, Surette FA, Hahn YS. The Immune Landscape in Nonalcoholic Steatohepatitis. Immune Netw 2016;16:147-58. [PMID: 27340383 DOI: 10.4110/in.2016.16.3.147] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
24 Mukherjee S, Haubner J, Chakraborty A. Targeting the Inositol Pyrophosphate Biosynthetic Enzymes in Metabolic Diseases. Molecules 2020;25:E1403. [PMID: 32204420 DOI: 10.3390/molecules25061403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
25 Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019;76:1541-58. [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 33.7] [Reference Citation Analysis]
26 Li CX, Ling CC, Shao Y, Xu A, Li XC, Ng KT, Liu XB, Ma YY, Qi X, Liu H, Liu J, Yeung OWH, Yang XX, Liu QS, Lam YF, Zhai Y, Lo CM, Man K. CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. Journal of Hepatology 2016;65:944-52. [DOI: 10.1016/j.jhep.2016.05.032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 7.2] [Reference Citation Analysis]
27 Dattaroy D, Seth RK, Das S, Alhasson F, Chandrashekaran V, Michelotti G, Fan D, Nagarkatti M, Nagarkatti P, Diehl AM, Chatterjee S. Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation. Am J Physiol Gastrointest Liver Physiol. 2016;310:G510-G525. [PMID: 26718771 DOI: 10.1152/ajpgi.00259.2015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
28 Ye D, Yang K, Zang S, Lin Z, Chau HT, Wang Y, Zhang J, Shi J, Xu A, Lin S, Wang Y. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2. J Hepatol 2016;65:988-97. [PMID: 27266617 DOI: 10.1016/j.jhep.2016.05.041] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 10.5] [Reference Citation Analysis]
29 Kang J, Shin J, Koh E, Ryu H, Kim HJ, Lee S. Opuntia ficus-indica seed attenuates hepatic steatosis and promotes M2 macrophage polarization in high-fat diet–fed mice. Nutrition Research 2016;36:369-79. [DOI: 10.1016/j.nutres.2015.12.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
30 Yan Y, Liu C, Zhao S, Wang X, Wang J, Zhang H, Wang Y, Zhao G. Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease. AMB Express 2020;10:101. [PMID: 32472368 DOI: 10.1186/s13568-020-01038-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
31 Li DY, Yang M, Edwards S, Ye SQ. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota? JPEN J Parenter Enteral Nutr. 2013;37:787-793. [PMID: 23538296 DOI: 10.1177/0148607113481623] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
32 Chi ZC. Pathogenesis of non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2017; 25(8): 670-683 [DOI: 10.11569/wcjd.v25.i8.670] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Mohamed IN, Li L, Ismael S, Ishrat T, El-Remessy AB. Thioredoxin interacting protein, a key molecular switch between oxidative stress and sterile inflammation in cellular response. World J Diabetes 2021; 12(12): 1979-1999 [DOI: 10.4239/wjd.v12.i12.1979] [Reference Citation Analysis]
34 Kiziltas S. Toll-like receptors in pathophysiology of liver diseases. World J Hepatol 2016; 8(32): 1354-1369 [PMID: 27917262 DOI: 10.4254/wjh.v8.i32.1354] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
35 Du J, Ji Y, Qiao L, Liu Y, Lin J. Cellular endo-lysosomal dysfunction in the pathogenesis of non-alcoholic fatty liver disease. Liver Int 2020;40:271-80. [PMID: 31765080 DOI: 10.1111/liv.14311] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
36 Hartmann P, Chen WC, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol 2012;3:402. [PMID: 23087650 DOI: 10.3389/fphys.2012.00402] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]
37 Hu J, Wang H, Li X, Liu Y, Mi Y, Kong H, Xi D, Yan W, Luo X, Ning Q, Wang X. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder. Theranostics 2020;10:9702-20. [PMID: 32863955 DOI: 10.7150/thno.44297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
38 Arias-Loste MT, Fábrega E, López-Hoyos M, Crespo J. The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. Biomed Res Int 2015;2015:319745. [PMID: 26491664 DOI: 10.1155/2015/319745] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
39 Wenfeng Z, Yakun W, Di M, Jianping G, Chuanxin W, Chun H. Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. Annals of Hepatology 2014;13:489-95. [DOI: 10.1016/s1665-2681(19)31247-5] [Cited by in Crossref: 58] [Article Influence: 7.3] [Reference Citation Analysis]
40 Dong TS, Jacobs JP. Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? Exp Biol Med (Maywood) 2019;244:408-18. [PMID: 30871368 DOI: 10.1177/1535370219836739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
41 Tan TC, Crawford DH, Jaskowski LA, Subramaniam VN, Clouston AD, Crane DI, Bridle KR, Anderson GJ, Fletcher LM. Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. Lab Invest. 2013;93:1295-1312. [PMID: 24126888 DOI: 10.1038/labinvest.2013.121] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 6.8] [Reference Citation Analysis]
42 Shu X, Wang M, Xu H, Liu Y, Huang J, Yao Z, Zhang L. Extracts of Salvia-Nelumbinis Naturalis Ameliorate Nonalcoholic Steatohepatitis via Inhibiting Gut-Derived Endotoxin Mediated TLR4/NF-κB Activation. Evid Based Complement Alternat Med 2017;2017:9208314. [PMID: 28831287 DOI: 10.1155/2017/9208314] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
43 Yin XL, Lu WN, Feng LY. Role of LPS/TLR4 signaling pathway in nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2013; 21(28): 2957-2962 [DOI: 10.11569/wcjd.v21.i28.2957] [Reference Citation Analysis]
44 Liu H, Ling CC, Yeung WHO, Pang L, Liu J, Zhou J, Zhang WY, Liu XB, Ng TPK, Yang XX, Lo CM, Man K. Monocytic MDSC mobilization promotes tumor recurrence after liver transplantation via CXCL10/TLR4/MMP14 signaling. Cell Death Dis 2021;12:489. [PMID: 33990548 DOI: 10.1038/s41419-021-03788-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Jin CJ, Engstler AJ, Ziegenhardt D, Bischoff SC, Trautwein C, Bergheim I. Loss of lipopolysaccharide-binding protein attenuates the development of diet-induced non-alcoholic fatty liver disease (NAFLD) in mice. J Gastroenterol Hepatol. 2016; Epub ahead of print. [PMID: 27404046 DOI: 10.1111/jgh.13488] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
46 Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. Front Med (Lausanne) 2020;7:361. [PMID: 32850884 DOI: 10.3389/fmed.2020.00361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
47 Xu M, Liu PP, Li H. Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases. Physiol Rev. 2019;99:893-948. [PMID: 30565509 DOI: 10.1152/physrev.00065.2017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
48 Ye D, Wang Y, Li H, Jia W, Man K, Lo CM, Wang Y, Lam KS, Xu A. Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice. Hepatology 2014;60:977-89. [PMID: 24590984 DOI: 10.1002/hep.27060] [Cited by in Crossref: 88] [Cited by in F6Publishing: 97] [Article Influence: 11.0] [Reference Citation Analysis]
49 Manti S, Romano C, Chirico V, Filippelli M, Cuppari C, Loddo I, Salpietro C, Arrigo T. Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic “mal-programming”. Hepat Mon. 2014;14:e17641. [PMID: 24829591 DOI: 10.5812/hepatmon.17641] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
50 Ding L, Oligschlaeger Y, Shiri-Sverdlov R, Houben T. Nonalcoholic Fatty Liver Disease. Handb Exp Pharmacol 2020. [PMID: 32185502 DOI: 10.1007/164_2020_352] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Huang L, Ding W, Wang MQ, Wang ZG, Chen HH, Chen W, Yang Q, Lu TN, Yang Q, He JM. Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4. J Int Med Res 2019;47:5239-55. [PMID: 31378113 DOI: 10.1177/0300060519859750] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
52 Chen J, Li J, Yiu JHC, Lam JKW, Wong CM, Dorweiler B, Xu A, Woo CW. TRIF-dependent Toll-like receptor signaling suppresses Scd1 transcription in hepatocytes and prevents diet-induced hepatic steatosis. Sci Signal 2017;10:eaal3336. [PMID: 28790196 DOI: 10.1126/scisignal.aal3336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
53 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839.2014.12.06] [Cited by in F6Publishing: 76] [Reference Citation Analysis]
54 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19:5250-5269. [PMID: 23394092 DOI: 10.2174/1381612811399990344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Wan X, Xu C, Yu C, Li Y. Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH. Can J Gastroenterol Hepatol 2016;2016:6489012. [PMID: 27446858 DOI: 10.1155/2016/6489012] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 8.7] [Reference Citation Analysis]
56 Hoo RL, Shu L, Cheng KK, Wu X, Liao B, Wu D, Zhou Z, Xu A. Adipocyte Fatty Acid Binding Protein Potentiates Toxic Lipids-Induced Endoplasmic Reticulum Stress in Macrophages via Inhibition of Janus Kinase 2-dependent Autophagy. Sci Rep 2017;7:40657. [PMID: 28094778 DOI: 10.1038/srep40657] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
57 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
58 Zang S, Wang L, Ma X, Zhu G, Zhuang Z, Xun Y, Zhao F, Yang W, Liu J, Luo Y, Liu Y, Ye D, Shi J. Neutrophils Play a Crucial Role in the Early Stage of Nonalcoholic Steatohepatitis via Neutrophil Elastase in Mice. Cell Biochem Biophys 2015;73:479-87. [PMID: 27352342 DOI: 10.1007/s12013-015-0682-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
59 Nie H, Yu X, He H, Zhou L, Li Q, Song C, Wang D, Ren T, Chen Z, Huang H, Dai X, Zhou Y. Hepatocyte miR-33a mediates mitochondrial dysfunction and hepatosteatosis by suppressing NDUFA5. J Cell Mol Med 2018;22:6285-93. [PMID: 30324697 DOI: 10.1111/jcmm.13918] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
60 Zhang B, Zhang C, Zhang X, Li N, Dong Z, Sun G, Sun X. Atorvastatin promotes AMPK signaling to protect against high fat diet-induced non-alcoholic fatty liver in golden hamsters. Exp Ther Med 2020;19:2133-42. [PMID: 32104276 DOI: 10.3892/etm.2020.8465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
61 Pasricha S, Kenney-Hunt J, Anderson K, Jafari N, Hall RA, Lammert F, Cheverud J, Green RM. Identification of eQTLs for hepatic Xbp1s and Socs3 gene expression in mice fed a high-fat, high-caloric diet. G3 (Bethesda) 2015;5:487-96. [PMID: 25617409 DOI: 10.1534/g3.115.016626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Jiang W, Liu J, Dai Y, Zhou N, Ji C, Li X. MiR-146b attenuates high-fat diet-induced non-alcoholic steatohepatitis in mice. J Gastroenterol Hepatol. 2015;30:933-943. [PMID: 25559563 DOI: 10.1111/jgh.12878] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
63 Yu SY, Xu L. The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention. J Appl Microbiol 2021;131:564-82. [PMID: 33411984 DOI: 10.1111/jam.14992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol 2020;20:40-54. [DOI: 10.1038/s41577-019-0198-4] [Cited by in Crossref: 179] [Cited by in F6Publishing: 171] [Article Influence: 59.7] [Reference Citation Analysis]
65 Tanti JF, Ceppo F, Jager J, Berthou F. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front Endocrinol (Lausanne). 2012;3:181. [PMID: 23316186 DOI: 10.3389/fendo.2012.00181] [Cited by in Crossref: 53] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
66 Akazawa Y, Nakao K. Lipotoxicity pathways intersect in hepatocytes: Endoplasmic reticulum stress, c-Jun N-terminal kinase-1, and death receptors. Hepatol Res 2016;46:977-84. [PMID: 26938481 DOI: 10.1111/hepr.12658] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
67 Mizunoe Y, Kobayashi M, Tagawa R, Nakagawa Y, Shimano H, Higami Y. Association between Lysosomal Dysfunction and Obesity-Related Pathology: A Key Knowledge to Prevent Metabolic Syndrome. Int J Mol Sci. 2019;20:3688. [PMID: 31357643 DOI: 10.3390/ijms20153688] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
68 Zhang M, Nie X, Yuan Y, Wang Y, Ma X, Yin J, Bao Y. Osteocalcin Alleviates Nonalcoholic Fatty Liver Disease in Mice through GPRC6A. Int J Endocrinol 2021;2021:9178616. [PMID: 33531899 DOI: 10.1155/2021/9178616] [Reference Citation Analysis]
69 Kishino A, Hayashi K, Hidai C, Masuda T, Nomura Y, Oshima T. XBP1-FoxO1 interaction regulates ER stress-induced autophagy in auditory cells. Sci Rep 2017;7:4442. [PMID: 28667325 DOI: 10.1038/s41598-017-02960-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
70 Jonscher KR, Bruce KD. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. Adv Exp Med Biol 2019;1134:33-58. [PMID: 30919331 DOI: 10.1007/978-3-030-12668-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Zhang Y, Lim CU, Sikirzhytski V, Naderi A, Chatzistamou I, Kiaris H. Propensity to endoplasmic reticulum stress in deer mouse fibroblasts predicts skin inflammation and body weight gain. Dis Model Mech 2021;14:dmm049113. [PMID: 34661243 DOI: 10.1242/dmm.049113] [Reference Citation Analysis]
73 Walenbergh SM, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol. 2013;58:801-810. [PMID: 23183522 DOI: 10.1016/j.jhep.2012.11.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
74 Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 2014; 20(44): 16452-16463 [PMID: 25469013 DOI: 10.3748/wjg.v20.i44.16452] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 79] [Article Influence: 11.5] [Reference Citation Analysis]
75 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
76 Yang YM, Wang Z, Matsuda M, Seki E. Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient L-amino acid-defined diet-induced murine model. Arch Pharm Res 2021;44:230-40. [PMID: 33486695 DOI: 10.1007/s12272-021-01309-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
77 Ibrahim SH, Hirsova P, Malhi H, Gores GJ. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci 2016;61:1325-36. [PMID: 26626909 DOI: 10.1007/s10620-015-3977-1] [Cited by in Crossref: 111] [Cited by in F6Publishing: 108] [Article Influence: 15.9] [Reference Citation Analysis]
78 Bjursell M, Wedin M, Admyre T, Hermansson M, Böttcher G, Göransson M, Lindén D, Bamberg K, Oscarsson J, Bohlooly-Y M. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One. 2013;8:e64721. [PMID: 23700488 DOI: 10.1371/journal.pone.0064721] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
79 Schuck RN, Zha W, Edin ML, Gruzdev A, Vendrov KC, Miller TM, Xu Z, Lih FB, DeGraff LM, Tomer KB. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. PLoS One. 2014;9:e110162. [PMID: 25310404 DOI: 10.1371/journal.pone.0110162] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
80 Baothman OA, Zamzami MA, Taher I, Abubaker J, Abu-Farha M. The role of Gut Microbiota in the development of obesity and Diabetes. Lipids Health Dis. 2016;15:108. [PMID: 27317359 DOI: 10.1186/s12944-016-0278-4] [Cited by in Crossref: 203] [Cited by in F6Publishing: 185] [Article Influence: 33.8] [Reference Citation Analysis]
81 Ferreira DF, Fiamoncini J, Prist IH, Ariga SK, de Souza HP, de Lima TM. Novel role of TLR4 in NAFLD development: Modulation of metabolic enzymes expression. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2015;1851:1353-9. [DOI: 10.1016/j.bbalip.2015.07.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
82 Sutter AG, Palanisamy AP, Lench JH, Esckilsen S, Geng T, Lewin DN, Cowart LA, Chavin KD. Dietary Saturated Fat Promotes Development of Hepatic Inflammation Through Toll-Like Receptor 4 in Mice. J Cell Biochem. 2016;117:1613-1621. [PMID: 26600310 DOI: 10.1002/jcb.25453] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
83 Chen Y, Yuan K, Zhang Z, Yuan F, Weng S, Yue H, He J, Chen Y. Identification and functional characterization of a solute carrier family 15, member 4 gene in Litopenaeus vannamei. Developmental & Comparative Immunology 2016;57:57-66. [DOI: 10.1016/j.dci.2015.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
84 Song CY, Zeng X, Wang Y, Shi J, Qian H, Zhang Y, Fang JQ, Sheng X, Zheng JM, Chen YX. Sophocarpine attenuates toll-like receptor 4 in steatotic hepatocytes to suppress pro-inflammatory cytokines synthesis. J Gastroenterol Hepatol 2015;30:405-12. [PMID: 25089018 DOI: 10.1111/jgh.12691] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
85 Takahara I, Akazawa Y, Tabuchi M, Matsuda K, Miyaaki H, Kido Y, Kanda Y, Taura N, Ohnita K, Takeshima F, Sakai Y, Eguchi S, Nakashima M, Nakao K. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice. PLoS One. 2017;12:e0170591. [PMID: 28278289 DOI: 10.1371/journal.pone.0170591] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
86 Xm S, Cc L, C L, Yf L, L C, Yz Z, Sj Y. TLR4 inhibition ameliorated glucolipotoxicity-induced differentiation suppression in osteoblasts via RIAM regulation of NF-κB nuclear translocation. Mol Cell Endocrinol 2021;543:111539. [PMID: 34929310 DOI: 10.1016/j.mce.2021.111539] [Reference Citation Analysis]
87 Du J, Zhang M, Lu J, Zhang X, Xiong Q, Xu Y, Bao Y, Jia W. Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK. Endocrine 2016;53:701-9. [DOI: 10.1007/s12020-016-0926-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
88 Jiang MP, Xu C, Guo YW, Luo QJ, Li L, Liu HL, Jiang J, Chen HX, Wei XQ. β-arrestin 2 attenuates lipopolysaccharide-induced liver injury via inhibition of TLR4/NF-κB signaling pathway-mediated inflammation in mice. World J Gastroenterol 2018; 24(2): 216-225 [PMID: 29375207 DOI: 10.3748/wjg.v24.i2.216] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
89 Beraldi EJ, Soares A, Borges SC, de Souza AC, Natali MR, Bazotte RB, Buttow NC. High-fat diet promotes neuronal loss in the myenteric plexus of the large intestine in mice. Dig Dis Sci 2015;60:841-9. [PMID: 25330870 DOI: 10.1007/s10620-014-3402-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
90 Aitbaev KA, Murkamilov IT, Fomin VV. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation]. Ter Arkh 2017;89:120-8. [PMID: 28914862 DOI: 10.17116/terarkh2017898120-128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
91 Day K, Dordevic AL, Truby H, Southey MC, Coort S, Murgia C. Transcriptomic changes in peripheral blood mononuclear cells with weight loss: systematic literature review and primary data synthesis. Genes Nutr 2021;16:12. [PMID: 34281497 DOI: 10.1186/s12263-021-00692-6] [Reference Citation Analysis]
92 Koo SY, Park EJ, Lee CW. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. Exp Mol Med 2020;52:1209-19. [PMID: 32770081 DOI: 10.1038/s12276-020-0480-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
93 Goel A, Gupta M, Aggarwal R. Gut microbiota and liver disease. J Gastroenterol Hepatol 2014;29:1139-48. [PMID: 24547986 DOI: 10.1111/jgh.12556] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
94 Ducheix S, Vegliante MC, Villani G, Napoli N, Sabbà C, Moschetta A. Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β. Cell Mol Life Sci 2016;73:3809-22. [PMID: 27522544 DOI: 10.1007/s00018-016-2331-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
95 Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10:627-636. [PMID: 23958599 DOI: 10.1038/nrgastro.2013.149] [Cited by in Crossref: 335] [Cited by in F6Publishing: 320] [Article Influence: 37.2] [Reference Citation Analysis]
96 Choi W, Namkung J, Hwang I, Kim H, Lim A, Park HJ, Lee HW, Han KH, Park S, Jeong JS, Bang G, Kim YH, Yadav VK, Karsenty G, Ju YS, Choi C, Suh JM, Park JY. Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nat Commun. 2018;9:4824. [PMID: 30446669 DOI: 10.1038/s41467-018-07287-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
97 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 2013;19:5250-69. [PMID: 23394092 DOI: 10.2174/13816128113199990344] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 11.8] [Reference Citation Analysis]
98 Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017;14:527-39. [PMID: 28676707 DOI: 10.1038/nrgastro.2017.72] [Cited by in Crossref: 176] [Cited by in F6Publishing: 168] [Article Influence: 35.2] [Reference Citation Analysis]
99 Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol 2020; 26(16): 1861-1878 [PMID: 32390698 DOI: 10.3748/wjg.v26.i16.1861] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
100 Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28 Suppl 1:68-76. [PMID: 23855299 DOI: 10.1111/jgh.12212] [Cited by in Crossref: 148] [Cited by in F6Publishing: 145] [Article Influence: 18.5] [Reference Citation Analysis]
101 Møhlenberg M, Terczynska-dyla E, Thomsen KL, George J, Eslam M, Grønbæk H, Hartmann R. The role of IFN in the development of NAFLD and NASH. Cytokine 2019;124:154519. [DOI: 10.1016/j.cyto.2018.08.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
102 Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: A comprehensive review. Journal of Autoimmunity 2013;46:97-111. [DOI: 10.1016/j.jaut.2013.06.013] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 8.6] [Reference Citation Analysis]
103 Zhang Y, Zhou G, Chen Z, Guan W, Zhang J, Bi M, Wang F, You X, Liao Y, Zheng S, Xu K, Yang H. Si-Wu-Tang Alleviates Nonalcoholic Fatty Liver Disease via Blocking TLR4-JNK and Caspase-8-GSDMD Signaling Pathways. Evid Based Complement Alternat Med 2020;2020:8786424. [PMID: 32849904 DOI: 10.1155/2020/8786424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 Roh YS, Seki E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol. 2013;28 Suppl 1:38-42. [PMID: 23855294 DOI: 10.1111/jgh.12019] [Cited by in Crossref: 147] [Cited by in F6Publishing: 150] [Article Influence: 18.4] [Reference Citation Analysis]
105 Wang N, Wang H, Yao H, Wei Q, Mao XM, Jiang T, Xiang J, Dila N. Expression and activity of the TLR4/NF-κB signaling pathway in mouse intestine following administration of a short-term high-fat diet. Exp Ther Med 2013;6:635-40. [PMID: 24137239 DOI: 10.3892/etm.2013.1214] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
106 Zhang DM, Jiao RQ, Kong LD. High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions. Nutrients. 2017;9:335. [PMID: 28353649 DOI: 10.3390/nu9040335] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 14.6] [Reference Citation Analysis]
107 Sellmann C, Priebs J, Landmann M, Degen C, Engstler AJ, Jin CJ, Gärttner S, Spruss A, Huber O, Bergheim I. Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. J Nutr Biochem. 2015;26:1183-1192. [PMID: 26168700 DOI: 10.1016/j.jnutbio.2015.05.011] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 13.1] [Reference Citation Analysis]
108 Schwenger KJP, Bolzon CM, Li C, Allard JP. Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria. Eur J Nutr 2019;58:1771-84. [PMID: 30306296 DOI: 10.1007/s00394-018-1844-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
109 Zwolak A, Słabczyńska O, Semeniuk J, Daniluk J, Szuster-Ciesielska A. Metformin Changes the Relationship between Blood Monocyte Toll-Like Receptor 4 Levels and Nonalcoholic Fatty Liver Disease-Ex Vivo Studies. PLoS One 2016;11:e0150233. [PMID: 26930651 DOI: 10.1371/journal.pone.0150233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
110 Pan Q, Zhang RN, Wang YQ, Zheng RD, Mi YQ, Liu WB, Shen F, Chen GY, Lu JF, Zhu CY, Zhang SY, Chen YM, Sun WL, Fan JG. Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World J Gastroenterol 2015; 21(28): 8605-8614 [PMID: 26229402 DOI: 10.3748/wjg.v21.i28.8605] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
111 Zhao GN, Zhang P, Gong J, Zhang XJ, Wang PX, Yin M, Jiang Z, Shen LJ, Ji YX, Tong J, Wang Y, Wei QF, Wang Y, Zhu XY, Zhang X, Fang J, Xie Q, She ZG, Wang Z, Huang Z, Li H. Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4. Nat Med. 2017;23:742-752. [PMID: 28481357 DOI: 10.1038/nm.4334] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 13.6] [Reference Citation Analysis]
112 Aron-wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clinical Microbiology and Infection 2013;19:338-48. [DOI: 10.1111/1469-0691.12140] [Cited by in Crossref: 141] [Cited by in F6Publishing: 134] [Article Influence: 15.7] [Reference Citation Analysis]
113 Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 2014;59:328-39. [PMID: 23703735 DOI: 10.1002/hep.26494] [Cited by in Crossref: 181] [Cited by in F6Publishing: 183] [Article Influence: 20.1] [Reference Citation Analysis]
114 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
115 Maeda H, Ishima Y, Saruwatari J, Mizuta Y, Minayoshi Y, Ichimizu S, Yanagisawa H, Nagasaki T, Yasuda K, Oshiro S, Taura M, McConnell MJ, Oniki K, Sonoda K, Wakayama T, Kinoshita M, Shuto T, Kai H, Tanaka M, Sasaki Y, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. J Control Release 2021;341:457-74. [PMID: 34856227 DOI: 10.1016/j.jconrel.2021.11.039] [Reference Citation Analysis]
116 Wree A, Inzaugarat ME, Feldstein AE. Transmembrane BAX Inhibitor motif-containing 1, a novel anti-inflammatory approach for nonalcoholic steatohepatitis treatment. Hepatology 2018;67:438-41. [PMID: 28859227 DOI: 10.1002/hep.29495] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
117 Shoieb SM, El-ghiaty MA, Alqahtani MA, El-kadi AO. Cytochrome P450-derived eicosanoids and inflammation in liver diseases. Prostaglandins & Other Lipid Mediators 2020;147:106400. [DOI: 10.1016/j.prostaglandins.2019.106400] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
118 Kew MC. Obesity as a cause of hepatocellular carcinoma. Annals of Hepatology 2015;14:299-303. [DOI: 10.1016/s1665-2681(19)31267-0] [Cited by in Crossref: 10] [Article Influence: 1.4] [Reference Citation Analysis]
119 Li J, Chen Q, Yi J, Lan X, Lu K, Du X, Guo Z, Guo Y, Geng M, Li D, Lu S. IFN-γ contributes to the hepatic inflammation in HFD-induced nonalcoholic steatohepatitis by STAT1β/TLR2 signaling pathway. Mol Immunol 2021;134:118-28. [PMID: 33770523 DOI: 10.1016/j.molimm.2021.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Khan MM, Yang WL, Wang P. ENDOPLASMIC RETICULUM STRESS IN SEPSIS. Shock 2015;44:294-304. [PMID: 26125088 DOI: 10.1097/SHK.0000000000000425] [Cited by in Crossref: 67] [Cited by in F6Publishing: 31] [Article Influence: 11.2] [Reference Citation Analysis]
121 Ma Y, Yang M, He Z, Wei Q, Li J. The Biological Function of Kupffer Cells in Liver Disease. In: Ghosh A, editor. Biology of Myelomonocytic Cells. InTech; 2017. [DOI: 10.5772/67673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
122 Gong Q, Hu Z, Zhang F, Cui A, Chen X, Jiang H, Gao J, Chen X, Han Y, Liang Q, Ye D, Shi L, Chin YE, Wang Y, Xiao H, Guo F, Liu Y, Zang M, Xu A, Li Y. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice. Hepatology 2016;64:425-38. [PMID: 26926384 DOI: 10.1002/hep.28523] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 10.5] [Reference Citation Analysis]
123 Li D, Wang X, Lan X, Li Y, Liu L, Yi J, Li J, Sun Q, Wang Y, Li H. Down-regulation of miR-144 elicits proinflammatory cytokine production by targeting toll-like receptor 2 in nonalcoholic steatohepatitis of high-fat-diet-induced metabolic syndrome E3 rats. Mol Cell Endocrinol. 2015;402:1-12. [PMID: 25534427 DOI: 10.1016/j.mce.2014.12.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
124 Sahin H, Borkham-Kamphorst E, do O NT, Berres ML, Kaldenbach M, Schmitz P, Weiskirchen R, Liedtke C, Streetz KL, Maedler K, Trautwein C, Wasmuth HE. Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes. Hepatology 2013;57:797-805. [PMID: 22996399 DOI: 10.1002/hep.26069] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
125 Chen D, Le TH, Shahidipour H, Read SA, Ahlenstiel G. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression. Cells 2019;8:E1324. [PMID: 31717860 DOI: 10.3390/cells8111324] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
126 Li S, Zeng XY, Zhou X, Wang H, Jo E, Robinson SR, Xu A, Ye JM. Dietary cholesterol induces hepatic inflammation and blunts mitochondrial function in the liver of high-fat-fed mice. J Nutr Biochem 2016;27:96-103. [PMID: 26391864 DOI: 10.1016/j.jnutbio.2015.08.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
127 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
128 Pickett-Blakely O, Young K, Carr RM. Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis. Cell Mol Gastroenterol Hepatol. 2018;6:451-462. [PMID: 30294653 DOI: 10.1016/j.jcmgh.2018.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
129 Liu B, Xiang L, Ji J, Liu W, Chen Y, Xia M, Liu Y, Liu W, Zhu P, Jin Y, Han Y, Lu J, Li X, Zheng M, Lu Y. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J Clin Invest 2021;131:e144801. [PMID: 34651580 DOI: 10.1172/JCI144801] [Cited by in F6Publishing: 1] [Reference Citation Analysis]